Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...